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Abstract
Background: Polycystic ovary syndrome (PCOS) is a common and chronic disorder
of endocrine glands where genetic factors play a major role in the susceptibility to
the disease. The cytochrome (CYP) 17 enzyme is essential for androgens biosynthesis.
Also, the CYP19 enzyme converts the androgens to the aromatic estrogens.
Objective:We aimed to investigate the association of CYP 17 MSP AI (T-34C) and CYP
19A1 (Trp39Arg) variants with the pathogenesis of PCOS in a population from Western
Iran with Kurdish ethnic background.
Materials and Methods: The present case-control study consisted of 50 patients with
PCOS and 109 controls. The CYP17 T-34C and CYP19A1 (Trp39Arg) polymorphisms
were identified by polymerase chain reaction-restriction fragment length polymor-
phism. The serum lipid and lipoprotein profile were detected by the Bionic Diagnostic
Kits. Estradiol, dehydroepiandrosterone (DHEA), and sex hormone-binding globulin
(SHBG) levels were measured using the chemiluminescent method.
Results: The serum levels of estradiol and SHBG in PCOS patients were lower than
controls (p<0.001 and p = 0.06, respectively). However, the level of DHEAwas higher (p
= 0.01) in patients compared to controls. The higher frequency of CYP17 TC genotype in
patients (30%) compared to controls (15.6%) was associated with 2.31-fold susceptibility
to PCOS (p = 0.038). The frequency of CYP19 TC genotype was 6.4% in controls and
10% in patients (p = 0.42).
Conclusion: The present study suggests that CYP17 TC genotype could be associated
with the risk of PCOS. Also, the study indicated the sex steroid hormones level
alteration and the lower level of SHBG in PCOS patients compared to healthy
individuals.
Key words: Cytochrome 17 (T-34C), Cytochrome 19 (Trp39Arg), Polycystic ovary
syndrome, Sex steroid hormones, Sex hormone-binding globulin.
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1. Introduction
Polycystic ovary syndrome (PCOS) is a common
and chronic disorder of endocrine glands affecting
up to 10% of the women at the age of fertility (1).
The principal cause of this syndrome is not known,
but studies have shown that genetic factors play
a major role in susceptibility to the disease (2).
The most important complications of the PCOS are
increased level of androgens, infertility, hirsutism,
dysfunction in ovulation and menstruation, and
metabolic disorders (3, 4). The 17α-hydroxylase/17–
20 lyase (CYP17A1) is a key enzyme in the path-
way of androgen biosynthesis that catalyzes the
conversion of pregnenolone to 17-hydroxy preg-
nenolone and the conversion of progesterone
to 17-hydroxy progesterone in adrenal gland and
ovary (5). The increased activity of this enzyme
results in increased synthesis and secretion of
androgens in PCOS (6). The CYP17A1 gene is
located on chromosome 10q24.3 and has eight
exons. There is a polymorphism at the promoter
region of the CYP17 MSP AI (T-34C/ rs743572)
that plays a role in the regulation of the gene
expression. The presence of this polymorphism
may lead to increased synthesis of androgens
(6, 7). There are inconsistent reports about the
role of CYP17 MSP Al (T-34C) polymorphism in
susceptibility to developing PCOS (6, 8, 9). The
CYP19A1 (aromatase) is a key enzyme in the
pathway of estrogen biosynthesis from androgen,
which is expressed in various tissues such as ovary,
breast, fatty tissue, etc. (10, 11). The CYP19 gene
is located on chromosome15q21.1 and contains 10
exons (12). A polymorphism in codon 39 of exon 2 of
the CYP19 (Trp39Arg/rs2236722) leads to reduced
activity of aromatase enzyme (13, 14). According to
the literature, there is no available study to examine
the role of CYP19A1 (Trp39Arg) polymorphism in
the pathogenesis of PCOS.
In circulation, estradiol, testosterone, and
dehydroepiandrosterone (DHEA) are transported
through binding to the sex hormone-binding
globulin (SHBG) and albumin that affect the
bioavailable fraction of the hormones (15).
The aims of this study were to identify the asso-
ciation between CYP17 MSP AI (T-34C/rs743572)
and CYP19 (Trp39Arg/rs2236722) polymorphisms
with susceptibility to PCOS and also with lipid
profile and sex hormone levels in a population from
Western Iran with ethnic background of Kurds.
2. Materials and Methods
In this present case-control study, 50 women
with confirmed PCOS (case) and 109 unrelated
age-matched healthy individuals without PCOS
(control) according to the Rotterdam criteria were
enrolled (16). Patients were individuals who referred
to the Kermanshah University of Medical Sciences
clinic. The mean age of case group was 23.6
± 5.3 yr (14–43 yr) and the controls were with
the mean age of 22.3 ± 4.0 yr (18–33 yr, p =
0.11). Controls were selected from students and the
staff of Kermanshah University of Medical Sciences
that did not have a history of hyperandrogenism
(the presence of hirsutism, acne or alopecia, and
menstrual irregularity).
Two criteria of hyperandrogenism (the presence
of hirsutism, acne or alopecia) and ovarian dys-
function (oligo- and/or an-ovulation and/or poly-
cystic ovaries detected by ultrasound scans) were
used for the diagnosis of PCOS. The exclusion
criteria were diseases affecting androgens pro-
duction such as congenital adrenal hyperplasia,
androgen-secreting tumors, and also the intake of
any medication that may affect the endocrine and
biochemical parameters at least three months prior
to enrolment.
Using the provided height and weight from each
individual the body mass index was calculated. All
women in this study were from the Kermanshah
province of Western Iran with ethnic background of
Kurds.
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2.1. Biochemical analysis
From each individual, a sample of venous blood
(10 milliliters) was collected at 9 am of the day 5
of the menstrual cycle under standard conditions
and used for biochemical and genetic analysis
according to the standard protocol.
The levels of blood parameters such as fasting
blood sugar (FBS), triglycerides, cholesterol, low-
density lipoprotein-cholesterol (LDL-C), and high-
density lipoprotein-cholesterol (HDL-C) were deter-
mined by using the Bionic Diagnostic Kits (Iran) on
Mindray BS-480 Chemistry Analyzer (China). Serum
estradiol level in the day 5 of the menstrual cycle
(follicular phase), the DHEA, and SHBG levels were
detected by the chemiluminescent method using
the Abbott Architect i1000 (Abbott Laboratory,
USA).
2.2. Genotype analysis
The standard method of phenol-chloroform was
used for extraction of DNA from the obtainedwhole
blood of each individual (17).
For detection of the CYP17 (T-34C) genotypes
the forward primer of 5′- CAT TCG CAC TCT GGA
GTC -3′ and the reverse primer of 5′- AGG CTC
TTG GGG TAC TTG -3′were used. The PCR cycling
conditions were the initial denaturation at 94∘C for
5 min followed by 30 cycles of 94∘C for 60 sec,
56∘C for 60 sec, 72∘C for 60 sec. At the end of
cycles a final elongation step at 72∘C for 7 min
was applied. Five microliters of the resulting PCR
products were electrophoresed on a 2% agarose
gel. The 414-bp PCR product was digested with
MSPAI restriction enzyme. The presence of C allele
resulted in digestion of the 414-bp fragment to two
fragments of 290- and 124-bp. While no digestion
was occurred in the presence of T allele and the
414-bp PCR product remained intact (18).
The CYP19A1 (Trp39Arg) polymorphism was
identified using the two-pair primers of the forward
primer 1: 5′-ATC TGT ACT GTA CAG CAC C-3′, and
the reverse primer 1: 5′ -ATG TGC CCT CAT AAT
TCC G-3′, the forward primer 2: 5′-GGC CTT TTT
CTC TTG GTG T-3′ and the reverse primer 2: 5′-
CTC CAA GTC CTC ATT TGC T-3′. PCR reaction
was carried out with a total volume of 25microliters
containing 100 ng of genomic DNA, 2.5 μl of 10X
PCR buffer, 200 μM dNTPs, 1.5 mM MgCl2, 1 unit
of Taq DNA polymerase, and 20 pmol of each
primer. The PCR cycling conditions, after the initial
denaturation at 94∘C for 5 min, were as follows:
94∘C for 60 sec, 56∘C for 60 sec, 72∘C for 60
sec (30 cycles), followed by the final elongation at
72∘C for 7 min. The resulting PCR products were
visualized using electrophoresis on a 2% agarose
gel. In the presence of T allele, a fragment with
200-bp is produced and the presence of C allele
produces a 264-bp fragment. Also, a common 427-
bp fragment was observed in the PCR products of
both alleles (19).
2.3. Ethical consideration
All individuals agreed to participate in the study
and signed a written informed consent before
participation. The Ethics Committee of Kermanshah
University of Medical Sciences approved the study
(code: 96500). The study was in accordance with
the principles of the Declaration of Helsinki II.
2.4. Statistical analysis
The frequencies of alleleswere calculated by the
chromosome counting method. The frequencies
of CYP17 T-34C and CYP19A1 (Trp39Arg) geno-
types and alleles have been compared between
patients and controls using chi-square test. Odds
ratios (OR) as an estimation of relative risk of
the disease and 95% confidence intervals (CIs)
were obtained by SPSS logistic regression. The
interaction between alleles of CYP17 and CYP19
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was determined using logistic regression model.
The independent-sample t-test was used to find
the correlation of biochemical parameters with
the studied polymorphisms between groups. Two-
tailed Student’s t-test and ANOVA analysis were
also used for comparison of quantitative data.
Statistical significance was assumed at the p-value
< 0.05. Statistical analysis was performed using
the statistical package for social sciences (SPSS)
logistic regression (SPSS, Inc., Chicago, IL) version
16.0.
3. Results
The clinical and biochemical characteristics of
patients and controls are demonstrated in Table
I. Comparing biochemical parameters between
patients and controls indicated a significantly lower
level of estradiol in patients compared to controls
(p < 0.001). Also, a near to significant lower level
of SHBG was observed in patients than controls (p
= 0.06). However, the DHEA level was significantly
higher in patients compared to controls (p = 0.01)
(Table I).
The distribution of CYP17 T-34C genotypes was
in Hardy–Weinberg equilibrium in both patients
(𝜒2 = 1.99, p > 0.1) and controls (𝜒2 = 0.78,
p > 0.1). Also, the distribution of genotypes of
CYP19 T > C was in Hardy–Weinberg equilibrium
in both PCOS patients (𝜒2 = 0.12, p > 0.1) and
controls (𝜒2 = 0.14, p > 0.1). Table II demonstrates
the distribution of CYP17 MSP AI (rs743572) and
CYP19 (rs2236722) genotypes and alleles in PCOS
patients and controls. The frequency of CYP17 TC
genotype was 30% in patients compared to 15.6%
in controls that was significantly associated with
2.31-fold susceptibility to PCOS (OR = 2.31 (95%
CI 1.04–5.14, p = 0.038). The genotype of CYP17
CC was not detected among both patients and
controls. Therewas a significantly higher frequency
of CYP17 C allele in patients (30%) compared to
controls (15.6%, p = 0.035) (Table II). The frequency
of CYP19 TC genotype was 6.4% in controls and
10% in patients (p = 0.42). Although, the presence
of CYP19 TC genotype increased the risk of PCOS
but it did not reach to a statistical significance [OR
= 1.61 (95%CI: 0.48–5.37, p = 0.43)] (Table II). Similar
to CYP17 polymorphism, no CYP19 CC genotype
was detected in both patients and controls. In
Table III, the biochemical parameters have been
compared between various genotypes of CYP17
MSP AI in patients and controls separately. Among
the controls, there was a significantly higher level
of FBS in the presence of CYP17 TC genotype (86.1
± 39.1 g/dl) compared to TT genotype (74 ± 10.2
g/dl, p = 0.01) (Table III). We observed lower levels
of estradiol and SHBG and a higher concentration
of DHEA in PCOS women carrying the CYP17 TC
genotype compared to those carrier of TT geno-
type that did not reach to a statistical significant.
Comparing the biochemical and hormonal param-
eters between the patients and controls carriers of
CYP17 TT or TC genotype indicated the absence
of a significant difference except for significantly
higher estradiol level in controls with TT genotype
than patients with this genotype (133.7 ± 91.6 vs.
70.9 ± 44.2 pg/ml (p = 0.01). Table IV indicates
haplotype analysis of two CYP17MSP AI and CYP19
T > C polymorphisms in patients and controls.
Haplotype analysis demonstrated that in patients
compared to controls, there was a significantly
higher percentage of concomitant presence of
CYP17T and CYP19C alleles than the presence of
CYP17C and CYP19T as reference haplotype (𝜒2 =
5.09, p = 0.024) (Table IV).
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Table I: The clinical and biochemical characteristics of patients with PCOS and controls.
Variables Patients (n = 50) Controls (n = 109) p
Age (years) 23.6 ± 5.3 22.3 ± 4 0.11
BMI (Kg/m2) 23.7 ± 4.9 22.3 ± 3.7 0.4
FBS (mg/dl) 78.5 ± 13.2 75.9 ± 14.8 0.36
Cholesterol (mg/dl) 131.1 ± 32.7 124.1 ± 28.6 0.17
TG (mg/dl) 87.9 ± 51.5 76.9 ± 33.8 0.11
HDL-C (mg/dl) 45.5 ± 11.7 41.6 ± 10.1 0.03
LDL-C (mg/dl) 73.9 ± 26.5 70.5 ± 21 0.38
Estradiol (pg/ml) 70 ± 45.5 130 ± 92 < 0.001
SHBG (pg/ml) 52.2 ± 24.5 64.6 ± 42.9 0.06
DHEA (pg/ml) 278.7 ± 148.7 215.4 ± 142 0.01
Systolic blood pressure
(mmHg)
100.2 ± 11.6 99.6 ± 13.3 0.79
Diastolic blood pressure
(mmHg)
71.6 ± 9.9 73 ± 10.5 0.42
The student’s t-test was used for comparing parameters between two groups. Data presented as mean ± SD
Note: BMI: Body mass index; FBS: Fasting blood sugar; TG: Triglyceride; HDL-C: High-density lipoprotein
cholesterol; LDL-C: Low-density lipoprotein cholesterol; SHBG: Sex hormone-binding globulin; and DHEA:
Dehydroepiandrosterone
Table II: The frequency of CYP19 T > C (rs2236722) and CYP17 MSP AI (rs743572) genotypes and alleles in patients with PCOS
and controls.
Genotypes Controls (n = 109) Patients (n = 50) 𝜒2 p
CYP19T > C
TT 102 (93.6) 45 (90) 0.62 0.42
TC 7 (6.4) 5 (10)
OR = 1.61 (95% CI: 0.48–5.37, p = 0.43)
Alleles
T 204 (93.6) 90 (90) 0.62 0.42
C 14 (6.4) 10 (10)
CYP17 MSP AI
TT 92 (84.4) 35(70) 4.42 0.035
TC 17 (15.6) 15 (30)
OR = 2.31 (95% CI: 1.04–5.14, p = 0.038)
Alleles
T 184 (84.4) 70 (70) 4.42 0.035
C 34 (15.6) 30 (30)
OR = 2.31 (95% CI: 1.04–5.14, p = 0.038)
Data presented as n (%).
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Table III: Comparison of biochemical parameters according to CYP17AI genotypes in all studied individuals.
Parameters Patients (n = 50) Controls (n = 109)
TC TT p TC TT p
BMI (Kg/m2) 24.7 ± 5.6 23.3 ± 4.6 0.34 20.9 ± 4.4 22.5 ± 3.5 0.10
FBS (mg/dl) 76.6 ± 11.6 79.4 ± 13.9 0.49 86.1 ± 39.1 74 ± 10.2 0.01
TG (mg/dl) 77.8 ± 43.7 92.4 ± 54.6 0.36 68.6 ± 22.1 78.5 ± 35.4 0.28
HDL-C (mg/dl) 47.6 ± 13.9 44.6 ± 10.6 0.42 43.2 ± 10.9 41.3 ± 10 0.49
LDL-C (mg/dl) 75.9 ± 31.5 73 ± 24.5 0.73 69.4 ± 14.6 70.7 ± 22.1 0.82
Cholesterol
(mg/dl)
129.8 ± 36.9 131.7 ± 31.3 0.85 124.4 ± 19.8 124 ± 30 0.96
Estradiol (pg/ml) 67.7 ± 50.1 70.9 ± 44.2 0.83 108.8 ± 95 133.7 ± 91.6 0.33
SHBG (pg/ml) 49.9 ± 20.9 53.2 ± 26.2 0.66 66.5 ± 30.3 64.3 ± 45 0.85
DHEA (pg/ml) 303.3 ± 151.5 267.9 ± 148.4 0.44 200.6 ± 148.9 218.1 ± 141.4 0.6
Systolic blood
pressure (mmHg)
102.6 ± 10.3 99.1 ± 12.2 0.33 105.2 ± 13.2 98.5 ± 13.1 0.056
Diastolic blood
pressure (mmHg)
72.6 ± 9.6 71.1 ± 10.2 0.62 74.1 ± 8.7 72.8 ± 10.9 0.64
Data presented as mean ± SD.
Note: BMI: Body mass index; FBS: Fasting blood sugar; TG: Triglyceride; HDL-C: High-density lipoprotein
cholesterol; LDL-C: Low-density lipoprotein cholesterol; SHBG: Sex hormone-binding globulin; and DHEA:
Dehydroepiandrosterone
Table IV: The synergism effect of CYP17 MSP AI (rs743572) and CYP19A1 (rs2236722) polymorphisms in patients with PCOS and
controls.
CYP17AI CYP19A1 Controls n = 109 Patients n = 50 𝜒2 p
T T 17 (15.6%) 13 (26%) – –
C T 85 (78%) 32 (64%) *2.87 **5.09 *0.09 **0.024
C C 7 (6.4%) 3 (6%) *0.55 0.45
T C 0 2 (4%) *2.41 0.12
Note: Overall: 𝜒2 = 7.24; p = 0.064; *Compared to reference; and **Compared to CYP17T and CYP19C
4. Discussion
A genetic basis for susceptibility to PCOS has
been suggested (2). The enzyme of CYP17 is
essential for androgen biosynthesis in the adrenal
gland and ovary. The presence of CYP17 C allele
(the A2 allele, rs743572) has been hypothesized
to create an additional Sp1-binding site which
increased the activity of promoter and enhanced
the gene expression (20).
The current study revealed that the CYP17 TC
genotype was associated with 2.31-fold increased
risk of PCOS. It seems increased risk of PCOS
in the presence of CYP17 TC genotype could be
attributed to higher promoter activity in the pres-
ence of this genotype compared to TT genotype.
The CYP17 CC genotype was not detected among
our studied samples because the homozygosity
for the C allele is rare in the populations (21,
22).
A study carried out by Pusalkar and colleagues
(23) demonstrated the high frequency of CYP17
C allele in PCOS patients compared to controls.
Similar to the report of Pusalkar and colleagues
(23), the current study indicated that the frequency
of C allele was significantly increased in women
with PCOS compared to the controls and the CYP17
(T-34C) polymorphism enhanced the risk of PCOS.
However, in a study conducted in China, the
frequency of genotypes of the CYP17 (T-34C)
polymorphism was not significantly different
between women with PCOS and healthy controls
(5). A meta-analysis by Li and coworkers (6)
demonstrated the absence of relationship between
CYP17 (T-34C) variants and increased risk of
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PCOS among Caucasian and Asian populations.
Also, some studies have shown no correlation
between CYP17 (T-34C) alleles and PCOS (8,
24, 25). Controversial reports related to the
association of CYP17 (T-34C) gene polymorphism
with susceptibility to PCOSmight be due to various
frequencies of the polymorphism among different
populations and the effect of sample size.
In our study non-significant lower levels of
estradiol and SHBG and a higher concentration
of DHEA in PCOS women with CYP17 TC geno-
type compared to women with TT genotype was
detected. Although, the presence of CYP17 (T-34C)
polymorphism enhances the promoter activity and
increases the gene expression with subsequent
elevation of androgen production, it has not been
confirmed by experimental studies (26, 27). The
mechanism by which the CYP17 (-T34C) polymor-
phismmight increase the serum level of sex steroid
hormones has not been identified. However, it
might be due to the effects that have not yet been
elucidated or the polymorphism could be in link-
age disequilibrium with another polymorphism that
leads to the CYP17 enzyme function alteration (27).
In the present study, no significant difference
was found in the frequency of different CYP19A1
(Trp39Arg) genotypes between patients with
PCOS and controls. Also, the association of CYP19
TC genotype with the risk of PCOS did not reach
to a statistical significance. There is no available
study to examine the role of CYP19 A1 (Trp39Arg)
variants in the pathogenesis of PCOS. In the
present study, the CYP19 A1 (Trp39Arg) was not
associated with the risk of PCOS. However, a
different polymorphism in CYP19 gene (rs2414096)
has been reported to be associated with the risk
of PCOS among Iranian women (28).
Haplotype analysis indicated the lack of
significant difference between CYP17C/CYP19C
haplotype frequencies compared to the
reference haplotype of CYP17T/CYP19T. However,
concomitant presence of CYP17T and CYP19C
alleles had significantly higher frequency than the
combined presence of CYP17C and CYP19T as the
reference haplotype in patients.
There is high prevalence of lipid abnormalities in
women with PCOS (29). However, in our study, we
did not detect a significant difference in lipid profile
between PCOS patients and controls.
5. Conclusion
In conclusion, we found that the CYP17 (T-
34C) polymorphism increased the risk of PCOS.
However, our study indicated that the CYP19A1
(Trp39Arg) polymorphismmight not be a risk factor
for susceptibility to PCOS in our population. Also,
the present study detected an association between
PCOS with lower serum levels of SHBG and estra-
diol and higher DHEA concentration.
Limitation
The limitation of the present study is the low
sample size especially in patients with PCOS.
Future Perspective
During the next 5–10 yr, more studies will be
conducted to elucidate the role of CYP17 (T-34C)
and CYP19A1 (Trp39Arg) gene variants and their
influence on the activities of CYP17 and CYP19
enzymes in PCOS among various populations.
Also, the molecular mechanism of CYP17 (T-34C)
and CYP19A1 (Trp39Arg) gene expression in rela-
tion to modulatory effects of epigenetic and envi-
ronmental factors will be more understood.
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